Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Baillie Gifford & Co. opened a new position in Stoke Therapeutics, buying 246,900 shares worth about $7.84 million and owning roughly 0.43% of the company at quarter-end.
• Analysts collectively rate STOK a Moderate Buy with an average price target of $41.83, and several firms have raised targets as high as $60 while issuing buy/outperform ratings.
• Insiders have been net sellers recently — a total of 69,699 shares (~$2.53M) sold in the last 90 days (including sales by Barry Ticho and CFO Thomas Leggett) — though insiders still hold about 9.5% of stock.

Baillie Gifford & Co. purchased a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 246,900 shares of the company's stock, valued at approximately $7,837,000. Baillie Gifford & Co. owned about 0.43% of Stoke Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after buying an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Stoke Therapeutics by 21.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock valued at $11,053,000 after buying an additional 293,072 shares in the last quarter. Jane Street Group LLC increased its position in Stoke Therapeutics by 125.2% during the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock valued at $179,000 after buying an additional 15,001 shares in the last quarter. JPMorgan Chase & Co. increased its position in Stoke Therapeutics by 26.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company's stock valued at $291,000 after buying an additional 5,398 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Stoke Therapeutics by 33.9% during the 2nd quarter. Rhumbline Advisers now owns 66,419 shares of the company's stock valued at $754,000 after purchasing an additional 16,820 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on STOK shares. Loop Capital set a $35.00 price target on shares of Stoke Therapeutics in a research note on Monday, January 5th. Wolfe Research started coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an "outperform" rating and a $40.00 price target on the stock. Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, March 20th. HC Wainwright upped their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Finally, Guggenheim initiated coverage on Stoke Therapeutics in a report on Thursday, February 5th. They issued a "buy" rating and a $60.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.83.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 6,686 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $209,539.24. Following the transaction, the insider owned 40,798 shares of the company's stock, valued at approximately $1,278,609.32. This trade represents a 14.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $74,651.88. Following the completion of the transaction, the chief financial officer directly owned 10,172 shares in the company, valued at $318,790.48. This represents a 18.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 69,699 shares of company stock valued at $2,526,714 in the last 90 days. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $35.05 on Tuesday. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -292.06 and a beta of 1.22. Stoke Therapeutics, Inc. has a one year low of $6.89 and a one year high of $40.22. The stock's fifty day moving average is $33.77 and its 200-day moving average is $31.38.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.97) EPS for the quarter. The company had revenue of $1.40 million for the quarter. Stoke Therapeutics had a negative net margin of 3.73% and a negative return on equity of 2.05%. Analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.